In syngenic mouse models of melanoma carrying a BRAFV600E driver mutation, B-RAF inhibitors have been shown to increase antigen presentation, antigen-specific T-cell recognition and improved T-cell effector function,32,33 suggesting that combination of targeted therapy with immunotherapy may improve patient outcome. This evidence concerns the gene BRAF and melanoma.